TH — Theratechnologies Share News
0.000.00%
Last trade - 00:00- CA$205.53m
- CA$252.52m
- $85.87m
Brief: Theratechnologies Announces First Patient Dosed In Phase 1 Clinical Trial Of TH1902
Brief: Theratechnologies Announces Fourth Quarter And Fiscal Year 2020 Results
Brief: Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast Track Designation For The Treatment Of Sortilin-Expressing Cancers
Brief: Piramal Pharma Says Piramal Pharma Solutions Announces Sterile Fill/Finish Program With Theratechnologies For Th1902 Peptide-Drug Conjugate
Canada Research Roundup: Boralex, Fortuna Silver Mines, Theratechnologies
Brief: Theratechnologies Announces $40 Mln Bought-Deal Public Offering Of Units
Brief: Theratechnologies Announces $40 Mln Bought-Deal Public Offering Of Units
Brief: Theratechnologies Announces Preliminary Q4 And Full Year 2020 Revenues
Brief: Theratechnologies Inc Announces New Findings For Lead Investigational Compound Th1902 For Treatment Of Several Additional Cancers
Brief: Theratechnologies Announces Data From Oral Presentation At Aasld Showing How Tesamorelin Can Reduce Fibrosis And Nash
Brief: Theratechnologies Announces Departure Of Chief Commercial Officer
Theratechnologies: Soars on U.S. patent for NASH disease treatment
Brief: Theratechnologies Confirms Issuance Of U.S. Patent Covering The Use Of Tesamorelin In The Treatment Of Individuals Suffering From Nafld/Nash
Brief: Theratechnologies Sees Q3 2020 Revenue C$13.8 Million To C$14.2 Million
Brief: Theratechnologies To Develop Tesamorelin For The Treatment Of NASH In The General Population
Theratechnologies: Surges on positive data from HIV-associated NASH drug
Brief: Theratechnologies Reports Tesamorelin Improves Liver Health
Brief: Theratechnologies Reports Q2 Loss Per Share Of $0.08
Brief: Theratechnologies Inc Confirms Bioequivalence Of New Tesamorelin Formulation